Previous 10 | Next 10 |
Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01...
Company Executives Available to Meet with Investment Professionals January 8-10 in San Francisco Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMON...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...
Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutic...
Lanvin Group Holdings Limited (LANV) is expected to report for quarter end 2023-09-30 Sonnet BioTherapeutics Holdings Inc. (SONN) is expected to report for Q4 2023 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q2 2024 Gelesis Holdings, Inc. (GLSHQ) is expected to repor...
JanOne Inc. (JAN) is expected to report for Q4 2023 Staffing 360 Solutions Inc. (STAF) is expected to report $-0.31 for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to report for quarter end 2023-09-30 Quotient Limited (QTNTQ) is expected to report for quarter ...
Nippon Paint Holdings Co. Ltd. (NPCPF) is expected to report for Q3 2023 SMC Corporation ADR (SMCAY) is expected to report for Q2 2024 Arcimoto Inc. (FUV) is expected to report for Q3 2023 Ever-Glory International Group Inc. (EVKG) is expected to report for quarter end 2023-09-30 ...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell therapies with a focus on immu...
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Scans of this first patient in the second cohort show 8.5% reduction in tumor size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Compa...
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel ™ (KB-GDT-01), Kiromic’s all...
Follow-up Scans Show Continued Stable Disease in First Patient Cohort Company to Apply for FDA Fast Track Designation Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces consistent favorable safety, tolerability, and e...